Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded
randomized study. The active treatment group will have sevoflurane applied at approximately 1
ml/cm2 at the start of wound treatment, the control group will only have a standard rinse
solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be
carried out in the standard manner. The duration of the study will be 5 days; if the defect
heals earlier, it will be terminated early.
Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire
Parameters to be monitored will be pain intensity, microbial colonization, appearance and
size of the defect